http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2322203-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8ef8acc27b4252e343aa5da877c870d2 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-78 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-78 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-056 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18 |
| filingDate | 1999-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5da1132b61683bd4c5eefb3db042ada9 |
| publicationDate | 1999-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2322203-A1 |
| titleOfInvention | 4,4-disubstituted-3,4-dihydro-2(1h)-quinazolinthione derivatives, their preparation and their use as hiv reverse transcriptase inhibitors |
| abstract | The present invention relates to 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinthiones of formula (I), wherein: R1 is C1-3 alkyl substituted with 1-7 halogen; R2 is selected from C1-5 alkyl substituted with 1-2 R4, C2-5 alkenyl substituted with 1-2 R4, and C2-5 alkynyl substituted with 1 R4; R4 is selected from C3-5 cycloalkyl substituted with 0-2 R3, phenyl substituted with 0-5 R3, and a 5- 6-membered heterocyclic system containing 1-3 heteroatoms selected from O, N, and S, substituted with 0-2 R3; and compounds of formula (II), wherein R2 is CC-R4a; R4a is selected from methyl, ethyl, n-propyl, i-propyl, i-butyl, t-butyl, and i-pentyl; R3 at each occurrence, is independently selected from C1-4 alkyl, OH, C1-4 alkoxy, F, Cl, Br, I, NR5R5a, NO2, CN, C(O)R6, NHC(O)R7, and NHC(O)NR5R5a; alternatively, if two R3's are present and are attached to adjacent carbons, then they may combine to form -OCH2O-; R8 is selected from H, C3-5 cycloalkyl, and C1-3 alkyl; and n is selected from 0, 1, 2, 3, and 4 or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HIV reverse transcriptase, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent. |
| priorityDate | 1998-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 190.